Safety and efficacy of intravenous belimumab in children with systemic lupus erythematosus: results from a randomised, placebo-controlled trial

OBJECTIVES: This ongoing Phase-2, randomised, placebo-controlled, double-blind study evaluated the efficacy, safety and pharmacokinetics of intravenous belimumab in childhood-onset systemic lupus erythematosus (cSLE). METHODS: Patients (5 to 17 years) were randomised to belimumab 10 mg/kg intravenou...

Descripción completa

Detalles Bibliográficos
Autores principales: Brunner, Hermine I, Abud-Mendoza, Carlos, Viola, Diego O, Calvo Penades, Inmaculada, Levy, Deborah, Anton, Jordi, Calderon, Julia E, Chasnyk, Vyacheslav G, Ferrandiz, Manuel A, Keltsev, Vladimir, Paz Gastanaga, Maria E, Shishov, Michael, Boteanu, Alina Lucica, Henrickson, Michael, Bass, Damon, Clark, Kenneth, Hammer, Anne, Ji, Beulah N, Nino, Antonio, Roth, David A, Struemper, Herbert, Wang, Mei-Lun, Martini, Alberto, Lovell, Daniel, Ruperto, Nicolino
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Systemic Lupus Erythematosus
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7509523/
https://www.ncbi.nlm.nih.gov/pubmed/32699034
http://dx.doi.org/10.1136/annrheumdis-2020-217101

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7509523/
https://www.ncbi.nlm.nih.gov/pubmed/32699034
http://dx.doi.org/10.1136/annrheumdis-2020-217101

Ejemplares similares